EPIMINDER LIMITED (EPI)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EPI - EPIMINDER LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -2.1
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.05

23 Dec
2025

0.010

OPEN

$1.12

0.96%

HIGH

$1.12

88,008

LOW

$1.05

TARGET
$2.33 121.9% upside
FNARENA'S MARKET CONSENSUS FORECASTS
EPI: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 14.7 - 24.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-14.7
DPS All xxx0.0
Sales/Revenue xxx0.0 M
Book Value Per Share xxx-17.4
Net Operating Cash Flow xxx-17.0 M
Net Profit Margin xxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-
Return on Invested Capital xxx-167.36 %
Return on Assets xxx-113.24 %
Return on Equity xxx-
Return on Total Capital xxx-107.34 %
Free Cash Flow ex dividends xxx-17.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx8 M
Long Term Debt xxx48 M
Total Debt xxx56 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx9 M
Price To Book Value xxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx0.0 M
Capex % of Sales xxx-
Cost of Goods Sold xxx0 M
Selling, General & Admin. Exp & Other xxx27 M
Research & Development xxx12 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

09/12/2025

1

Initiation of coverage with Speculative Buy

$2.33

121.90%

Morgans initiated coverage of Epiminder with a Speculative Buy rating and target price of $2.33.

The company is developing the FDA-approved Minder sub-scalp electroencephalography (EEG) for continuous brain monitoring to improve epilepsy diagnosis and treatment vs short EEG tests.

It will initially target drug-resistant epilepsy patients with inconclusive EEGs, with up to 45,000 US patients per year and a US$1.1bn market, ahead of a phased US launch in 2H26.

The broker expects the $125m IPO raising and cash reserves to last until the end of 2027, helping to build the next-gen G1 Minder, and set up US commercial capabilities. Assumption is for reasonable revenue generation in FY29.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -24.00 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -17.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

EPI STOCK CHART

FNArena News on EPI

1
Next Week At A Glance – 22-24 Dec 2025

Dec 19 2025 - Weekly Reports
2
Next Week At A Glance – 8-12 Dec 2025

Dec 05 2025 - Weekly Reports